Mucosal AIDS vaccines: current status and future directions (Q35851782)

10 August 2017

1 reference

title

Mucosal AIDS vaccines: current status and future directions (English)

1 reference

10 August 2017

3

Jay A Berzofsky

1 reference

10 August 2017

Igor M Belyakov

1

1 reference

PubMed ID

15285706

10 August 2017

Jeffrey D Ahlers

series ordinal

2

1 reference

PubMed ID

15285706

10 August 2017

language of work or name

1 reference

1 August 2004

1 reference

Expert Review of Vaccines

10 August 2017

1 reference

10 August 2017

3

1 reference

10 August 2017

4 Suppl

1 reference

10 August 2017

S65-73

1 reference

A review of vaccines for HIV prevention.

10 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Progress in the development of an HIV-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Immune control of HIV-1 after early treatment of acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Cytotoxic T lymphocytes specific for the simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Molecular mechanisms and biological significance of CTL avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Quantifying the uncertainty in forecasts of anthropogenic climate change

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Protection against vaginal SIV transmission with microencapsulated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

CpG motifs in bacterial DNA and their immune effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S65

21 January 2018

Identifiers

DOI

10.1586/14760584.3.4.S65

1 reference

10 August 2017

1 reference

PubMed ID

15285706